The 36-month beta value for CYTK is also noteworthy at 0.77. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CYTK is 113.74M, and at present, short sellers hold a 15.23% of that float. The average trading volume of CYTK on October 18, 2024 was 1.24M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CYTK) stock’s latest price update
The stock of Cytokinetics Inc (NASDAQ: CYTK) has decreased by -1.36 when compared to last closing price of 55.28. Despite this, the company has experienced a 2.60% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-16 that NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM Beyond The Heart” for Health Care Professionals SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company’s cardiac myosin modulation programs and global commercial launch readiness for aficamten at its Investor and Analyst Day, “Heart Forward: Advancing Cardiac Myosin Modulation,” today at 8:30 AM Eastern Time in New York and streamed live online.
CYTK’s Market Performance
CYTK’s stock has risen by 2.60% in the past week, with a monthly drop of -2.52% and a quarterly drop of -3.33%. The volatility ratio for the week is 3.11% while the volatility levels for the last 30 days are 3.44% for Cytokinetics Inc The simple moving average for the past 20 days is 1.12% for CYTK’s stock, with a -14.22% simple moving average for the past 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Goldman repeating the rating for CYTK by listing it as a “Neutral.” The predicted price for CYTK in the upcoming period, according to Goldman is $60 based on the research report published on August 13, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $92, previously predicting the price at $61. The rating they have provided for CYTK stocks is “Neutral” according to the report published on January 24th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to CYTK, setting the target price at $90 in the report published on January 05th of the current year.
CYTK Trading at -1.00% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.54% of loss for the given period.
Volatility was left at 3.44%, however, over the last 30 days, the volatility rate increased by 3.11%, as shares sank -1.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.46% upper at present.
During the last 5 trading sessions, CYTK rose by +2.60%, which changed the moving average for the period of 200-days by -35.18% in comparison to the 20-day moving average, which settled at $53.92. In addition, Cytokinetics Inc saw -34.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 7,300 shares at the price of $54.19 back on Oct 15 ’24. After this action, Malik Fady Ibraham now owns 116,920 shares of Cytokinetics Inc, valued at $395,554 using the latest closing price.
FADY MALIK, the Officer of Cytokinetics Inc, proposed sale 7,300 shares at $54.19 during a trade that took place back on Oct 15 ’24, which means that FADY MALIK is holding shares at $395,578 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -161.48 for the present operating margin
- -28.87 for the gross margin
The net margin for Cytokinetics Inc stands at -173.99. The total capital return value is set at -0.36.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 6.2. The interest coverage ratio of the stock is -6.96.
Currently, EBITDA for the company is -484.31 million with net debt to EBITDA at -1.23. When we switch over and look at the enterprise to sales, we see a ratio of 2238.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.39.
Conclusion
In summary, Cytokinetics Inc (CYTK) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
